

# ABSTRACT SUBMISSION GUIDELINES

## 1. General Information

- Submission is only available online at <http://submission.summitmd.com/login.php?iid=40>.
- Submission period is until **November 13, 2020**, please meet the deadline. For submission, join [www.summitmd.com](http://www.summitmd.com), if you are not a member yet.
- If you have several email accounts, we recommend you **NOT** to use Hotmail account for your ID; it blocks emails from us. It would be difficult to reach you for further notifications (acceptance alert, invitation, etc.).
- In case you are not able to recall your login Username/Password, please click "Forgot Your Password?"

## 2. Title

- The title of abstract should be within 300 bytes.
- It should be concise and specific, containing no abbreviations and indicating the nature of the investigation.
- The first letter of each word must be capitalized.

## 3. Author(s)

- The designation of single presenter is required to complete a submission.
- First author, presenter and co-author(s) can be the same person.
- Each Author's information must be completed for submission. **Be sure to proofread carefully** as the authors' information will be included in a JACC online supplement as well as e-poster uploaded onto the official website.
- Important notifications regarding your submission will be sent to the **submitter and designated presenter**. **Make sure all the contact information is correct.**

## 4. Abstract Categories

- Abstracts should involve the following disciplines in the field of cardiovascular medicine and intervention.
- Select one category that is closest to the subject of your abstract.
- If the category does not match the subject of the abstract, you may receive a low score from the reviewers.

### CORONARY

Acute Coronary Syndromes (STEMI, NSTEMI-ACS)  
Adjunctive Procedures (Thrombectomy, Atherectomy, Special Balloons)  
Bifurcation/Left Main Diseases and Intervention  
Cardiac Surgery/Hybrid Revascularization  
Chronic Total Occlusion  
Complex and Higher Risk Procedures for Indicated Patients (CHIP)  
Complications  
Drug-Eluting Balloons  
Hemodynamic Support and Cardiogenic Shock  
Pharmacology/Pharmacotherapy  
Stents (Bare-metal, Drug-eluting)

### ENDOVASCULAR

Aorta Disease and Intervention  
Carotid & Neurovascular Intervention  
Complications  
Hypertension Therapies and Renal Denervation  
Peripheral Vascular Disease and Intervention

### IMAGING AND PHYSIOLOGIC LESION ASSESSMENT

Imaging: Intravascular  
Imaging: Non-Invasive  
Physiologic Lesion Assessment  
Vulnerable Plaque

### STRUCTURAL HEART DISEASE

Congenital Heart Disease (ASD, PDA, PFO, VSD)  
Hypertrophic Obstructive Cardiomyopathy  
Left Atrial Appendage Closure

Pulmonary Intervention: CTEPH, PHTN  
Valvular Intervention: Aortic  
Valvular Intervention: Mitral or Tricuspid  
Others (Structural Heart Disease)

## OTHER

Basic Science, Animal Models and Preclinical Studies  
Cell Therapy and Angiogenesis  
Diabetes  
Genomics/Proteomics  
Innovative Devices and Futuristic Therapies  
Pre-Clinical/First In-Human Studies  
Quality, Guidelines and Appropriateness Criteria  
Renal Insufficiency and Contrast Nephropathy  
Vascular Access (Transradial)  
Women's Health Issues  
Others (Unclassified)

### 5. Abstract Content

- Abstracts must be submitted in English.
- Abstracts body consists of Background, Methods, Results, and Conclusion.
- Abstracts may be entered directly into the site or copied and pasted, however, be sure to check again whether the special characters or symbols are not broken.
- You can copy and paste an existing Excel table or create a new table using the provided system tools, however, be sure to check again whether the special characters or symbols are not broken.
- The maximum number of characters allowed in the body of the abstract is 2200 (approximately 300-350 words).  
Spaces are included.
- Use zeros before decimal points: 0.05, not .05.
- Use decimal points, not commas: 0.05, not 0,05.
- Use lowercase "p" values ( $p < 0.05$ ).
- Provide a manufacturer name and location in parentheses for all brand or trade names.
  - Never use the underline feature to denote the following symbols:  $\pm$ ,  $\leq$ ,  $\geq$ .
- Use space between numbers and symbols. (e.g.,  $3 \pm 4$ , not  $3\pm 4$ ; 3 mg, not 3mg).
- All measurements must include unit of measure (e.g., systolic blood pressure "140 mmHg", not just "140").
- For brand drugs, include generic names in parentheses.
- Do not include references, credits, or grant support.

### 6. Abstract Review

- All submitted abstracts will be thoroughly evaluated by official reviewers, and it will influence the allocation to two different types of sessions - *Late Breaking Clinical Trials Session* and *Abstract Presentation Session*.

### 7. Abstract Acceptance Notification

- An acceptance notification will be made on **January 15, 2021** to the designated presenter and the submitter.
- After the notification, presenters will be informed of their presentation date and time with specific guidelines for session.

### 8. Abstract Presentation

- All selected abstracts will be allocated to 1) *Late Breaking Clinical Trials Session* or 2) *Abstracts Presentation Session* based on the scores assigned by official reviewers.

#### 1) Late Breaking Clinical Trials Session

- Abstracts containing novel findings that may improve current practices will be presented at this session.
- Note that duplicate study will not be accepted.
- A cash reward & award certificate will be given to each LBCT presenter.
- LBCT will be featured in a *TCTAP's Daily News* as well as published in an online supplement of *The Journal of the American College of Cardiology (JACC)*.

## 2) Abstract Presentation Session

- Selected abstracts must be prepared in MS PowerPoint for both oral presentation and e-poster.
- All presenters get advantages when they apply for Best Young Scientist Award.
- Selected abstracts will be published in an online supplement of '*The Journal of the American College of Cardiology(JACC)*'.

## 9. Abstract Withdrawal

- Before November 20, 2020, you may log in and withdraw your submission at any time.
- After November 20, 2020, please email at [abstract@summitmd.com](mailto:abstract@summitmd.com) with your submission number and title to request withdrawal.
- A request for withdrawal must be made by March 31 , 2021.

## 10. No Show Policy

- If you are not available to make a presentation, please notify the secretariat in advance via e-mail at [abstract@summitmd.com](mailto:abstract@summitmd.com). If the scheduled presenter fails to appear in person or to send a replacement, and does not cancel the presentation before the meeting, that presenter may jeopardize future acceptance of Calls for Science.

## 11. Copyright Information

When abstracts are submitted, we assume that the authors grant copyright to the Congress Organization for publication on the website [www.summit-tctap.com](http://www.summit-tctap.com), [www.ap-valves.com](http://www.ap-valves.com) and [summitmd.com](http://summitmd.com). By submitting an abstract for the conference, the presenter verifies that the abstract's content and its conclusion should not have been published in any other meeting before our meeting.

## 12. Assistance

If you need help with your submission, please contact us at +82 2 3010 7251 or email [abstract@summitmd.com](mailto:abstract@summitmd.com).